Noncirrhotic portal hypertension in HIV infection

Current Opinion in Infectious Diseases

Volumn 24, Issue 1, 2011, Pages 12-18

  Vispo, Eugenia ^a   Morello, Judit ^a   Rodriguez Novoa, Sonia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

didanosine; hepatotoxicity; HIV; liver

Indexed keywords

ABACAVIR; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIDANOSINE; MERCAPTOPURINE; RIBAVIRIN; TIOGUANINE;

ALCOHOL ABUSE; ARTICLE; BACTERIAL TRANSLOCATION; BONE MARROW SUPPRESSION; DISEASE SEVERITY; ESOPHAGUS VARICES BLEEDING; FATTY LIVER; GASTROINTESTINAL HEMORRHAGE; HEMOLYTIC ANEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NONCIRRHOTIC PORTAL HYPERTENSION; PORTAL HYPERTENSION; PORTAL VEIN; PROPHYLAXIS; THROMBOSIS; VIRUS HEPATITIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOPSY; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; LIVER;

EID: 78751581836     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283420f08     Document Type: Article

References (45)

1. Weber R, Sabin C, Friis-Moller N, etal. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
3. Benhamou Y, Bochet M, Di Martino V, etal. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
4. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13.
5. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-1155.
6. Sulkowski M, MehtaS,Torbenson M, etal. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
7. Blackard J, Sherman K. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15:323-330.
8. Balagopal A, Philp F, Astemborski J, etal. HIV-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-233.
9. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
10. Ingiliz P, Valantin M, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in HIV-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-442.
11. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-182.
12. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-192.
13. Schiano T, Kotler D, Ferran E, Fiel M. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536-2540.
14. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103-107.
15. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with HIV-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167-1169.
16. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626-635.
17. Dinh M, Stosor V, Rao S, et al. Cryptogenic liver disease in HIV-seropositive men. HIV Med 2009; 10:447-453.
18. Chang P, Miquel R, Blanco JL, etal. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104:1707-1714.
19. Panos G, Farouk L, Stebbing J, et al. Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV. J Acquir Immune Defic Syndr 2009; 52:525-527.
20. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24:1171-1176.
21. Sandrine P, Sylvie A, Andre E, et al. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 2007; 21:1498-1499.
22. Sarin S, Kumar A. Noncirrhotic portal hypertension. Clin Liver Dis 2006; 10:627-651.
23. Harmanci O, Bayraktar Y. Clinical characteristics of idiopathic portal hypertension. World J Gastroenterol 2007; 13:1906-1911.
24. Hillaire S, Bonte E, Denninger MH, etal. Idiopathic noncirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:275-280.
25. Dhiman R, Chawla Y, Vasishta R, etal. Noncirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002; 17:6-16.
26. Arey B, Markov M, Ravi J, et al. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007; 21:1066-1068.
27. Mallet V, Vallet-Pichard A, Pol S. HIV-associated obliterative portopathy underlies unexplained aminotransferase elevations under antiretrovirals. Hepatology 2009; 50:660.
28. Chang P, Garcia-Pagan JC. Idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis 2010; 50:127-128.
29. Mendizabal M, Craviotto S, Chen T, et al. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol 2009; 8:390-395.
30. Podevin P, Spiridon G, Terris B, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006; 20:313-315.
31. Shastri S, Dubinsky M, Fred Poordad F, et al. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thiogua-nine therapy. Arch Pathol Lab Med 2004; 128:49-53. (Pubitemid 38049566)
32. Seiderer J, Zech C, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553-555.
33. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102:1518-1527. (Pubitemid 46976279)
34. DeLeve L. Hepatic microvasculature in liver injury. Semin Liver Dis 2007; 27:390-400.
35. Sabin C, Worm S, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1 426.
36. Kuller L, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
37. Strategies for Management of Antiretroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-F24.
38. Goicoechea M, McCutchan A. Abacavir and increased risk of myocardial infarction. Lancet 2008; 372:803-804.
39. Mallet V, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23:1511-1518.
40. Bihl F, Janssens F, Boehlen F, et al. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol 2010; 10:6.
41. Jiang W, Lederman M, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
42. Higgs J, Payne K, Roberts C, Newman W. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2009; 11:177-188.
43. Fellay J, Thompson A, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-408.
44. Vispo E, Maida I, Barreiro P, et al. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients. HIV Clin Trials 2008; 9:440-444.
45. Tateo M, Sebagh M, Bralet M, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in HIV-infected patients. Liver Transpl 2008; 14:1194-1198.